Rexahn Pharmaceuticals Licenses Potential Cancer Rxs from Korean Chemical Research Institute | GenomeWeb

Rexahn Pharmaceuticals said this week that it has exclusively licensed from the Korea Research Institute of Chemical Technology intellectual property related to a synthetic process for producing quinoxaline compounds as potential cancer therapies.

Under the terms of the agreement, Rexahn, based in Rockville, Md., said will acquire all intellectual property related to quinoxaline-piperazine derivatives that were synthesized under a previous joint research agreement between Rexahn and KRICT.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

Sponsored by
Agilent Technologies

This webinar will provide specific use cases from a molecular pathology lab demonstrating how an automated bioinformatics pipeline can improve somatic variant assessment and reporting.